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ABSTRACT 
This work focuses on regulatory T (Treg) cell biology in the context of defining the role of 
forkhead box protein 3 (FOXP3) isoform expression and Treg mediated suppression via 
CTLA-4 (cytotoxic T-lymphocyte-associated protein 4).  
Treg cells are crucial in maintaining immunological tolerance and they in part act by 
suppressing dendritic cells (DCs). Previous studies have demonstrated that Treg cells express 
the co-inhibitory receptor CTLA-4, which is essential for Treg cells ability to control the 
expression of the costimulatory molecules CD80/CD86 on DCs. In study I we generated a 
novel mouse strain that exclusively expresses the naturally occurring ligand-independent 
CTLA-4 isoform (liCTLA-4) in Treg cells only. This isoform cannot control CD80/CD86 
expression by direct binding to these molecules. One of the key findings in this study is that 
these Ctla4ex2fl/flFoxp3-Cre mice did not develop a lymphoproliferative phenotype early in life. 
When we extended our study, we saw that older Ctla4ex2fl/flFoxp3-Cre mice (6 months) 
developed an inflammatory phenotype in the lung. Interestingly, Ctla4ex2fl/flFoxp3-Cre mice 
had an increased number of Treg cells, in particular Treg cells lacking CD25 expression. The 
dramatic increase of Treg cells could potentially compensate for any functional impairment 
due to altered CTLA-4 expression. Thus, we isolated Treg cells for in vitro assays to further 
investigate Treg cell function using an DC suppression assay that we established. We found 
that Treg cells isolated from Ctla4ex2fl/flFoxp3-Cre were able to control CD80 and CD86 
expression. However, Treg cells isolated from Ctla4ex2fl/flFoxp3-Cre failed to support 
upregulation of PD-L2 on suppressed DCs. 
The transcription factor FOXP3 is a key regulator for Treg cell differentiation and is required 
to maintain their suppressive phenotype. FOXP3 occurs as four distinct isoforms, full-length 
FOXP3 and isoforms lacking exon 2 and or exon 7. In study II we determined the FOXP3 
isoform expression in plaques and blood from patients suffering from atherosclerotic disease. 
We found a positive correlation between FOXP3D2 splice variant expression and plaque 
stability in plaque tissue that was not apparent in blood. Another key finding from this study 
is that during Treg cell activation the overall upregulation of FOXP3 expression is mainly due 
to an increased expression of the isoform FOXP3D2. In study III and IV we reported on two 
patients with a novel frameshift mutation in the FOXP3 gene (NM_014009.3:c.305delT) 
located in exon 2 which results in a premature stop codon and consequently the loss of any 
isoforms expressing exon 2. Both patients had a very mild IPEX phenotype, which strongly 
suggests FOXP3D2 alone is able to at least partially maintain Treg cell development and 
function. Investigating the female carrier, we saw approximately 20% of the Treg pool had 
the c.305delT mutation not matching the expected 50% from random X-chromosome 
inactivation. RNA sequencing allowed us to identify a set of genes, several which previously 
have been demonstrated to regulate FOPX3 expression, that are specifically regulated by full-
length FOXP3. This gene set may explain the loss of c.305delT Treg cells and we currently favor 
the view that they regulate the lineage stability of Treg cells.  
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AIRE autoimmune regulator 
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PD-1 programmed cell death protein 1 
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ROR retinoic-acid-receptor-related orphan nuclear receptor 
STAT signal transducer and activator 
PTA peripheral tissue antigens 
TCR T cell receptor 
TGF transforming growth factor 
T cell T lymphocytes 
CTL CD8+ cytotoxic T cells 
Th cells CD4+ T helper cells 
nT cells naïve T cells 
Teff cells effector T cells  
Treg cells regulatory T-cells 
tTreg cells thymus-derived Treg cells 
pTreg cells periphery-derived Treg cells 
rTreg cells resting Treg cells 
aTreg cells activated Treg cells 
TLR toll-like receptor 
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1 INTRODUCTION 
1.1 THE IMMUNE SYSTEM 
The immune system consists of a network of organs, tissues and various types of specialized 
cells that together protect the body. This includes anatomical barriers like the skin and 
mucosal tissues, as our first line of defense. Additionally, the lymphatic system runs in parallel 
to the blood circulatory system and allows immune cells to traffic towards the destination 
where they perform their function. The lymphatic system functions both as a place for 
immune cell development, in the primary lymphoid organs (thymus and bone marrow) and 
as a site to orchestrate immune responses in secondary lymphoid organs (spleen and lymph 
nodes).  Next to exposure to a variety of potential infectious agents including bacteria, viruses, 
and parasites on a daily basis. The immune system also needs to respond towards internal 
threats like damaged or mutated cells. The primary function of the immune system is to 
answer with an immune response to clear or control the spread of a threat. An immune 
response includes several phases: (I) antigen recognition, (II) clearance and/or limitation, (III) 
a return to immune homeostasis and (IV) formation of memory (Murphy and Weaver, 2017). 
In the context of this thesis the phases involve (I) activation of naïve T cells (section 1.2.2 and 
2.1), (II) differentiation of Naïve T cells into effector T cells (section 1.2.3 and section 2.1), (III) 
limitation of T cell response (section 4) and (IV) T cell memory formation (section 1.2.3).  
Not all antigens recognition provokes an immune response and in certain situations it could 
even have an adverse effect. Inappropriate immune response may lead to development of 
chronic inflammation, which in turn is associated with the increased risk of cancer 
development and autoimmune disorders (Doria et al., 2012; Grivennikov et al., 2010). 
Therefore, the immune system not only needs to be capable to distinguish between self and 
foreign antigens but also between dangerous and non-dangerous antigens. This concept that 
the immune system as able to identify dangerous from non-dangerous antigens is called 
immunological tolerance and will be discussed in section 1.3.  
Throughout evolution, the immune system gained complexity through development of an 
innate and an adaptive arm, which today is present in higher vertebrates (Cooper and Alder, 
2006; Janeway, 1992). The innate immune system comprises the rapidly responding part of 
the immune system and innate immune cells include granulocytes, natural killer (NK) cells and 
professional antigen presenting cells (APC) like macrophages and dendritic cells (DC). Innate 
immune cells recognize a broad range of pathogen-associated molecules (PAMPs) via 
conserved receptors such as toll-like receptors (TLRs). TLR activation leads to the secretion of 
cytokines and chemokines, i.e. molecules that mediate cell signaling, differentiation and 
migration. One of the key roles of the innate immune response involves the recruitment and 
activation of the adaptive immune system. DCs are often seen as a key link in connecting the 
innate and adaptive immune response due to their ability to process and present antigens 
and consequently induce T cell activation (see section 1.2.2) (Murphy and Weaver, 2017). 
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The adaptive immune system consists of two major classes of cells, namely B cells and T cells. 
Both cells types share the ability to clonally expand after recognition of their cognate antigen 
and further develop into memory cells. They both arise from the same multi-potent 
hematopoietic stem cells in the bone marrow but they differ in their site of development. B 
cells develop in the bone marrow, whereas T cell progenitors migrate to the thymus where 
they further differentiate into naïve T cells (see section 1.2.1 on T cell development) (Takaba 
and Takayanagi, 2017). The key feature of B cells is production and secretion of highly specific 
antibodies during humoral immune responses (Pieper et al., 2013). T cells are divided into 
two functional classes, namely CD4+ T cells and CD8+ T cells.  CD4+ T cells support B cells during 
humoral response and CD8+ T cells can directly kill infected cells during cell mediated immune 
response (see section 1.2) (Murphy and Weaver, 2017).  
One of the main differences between the innate and adaptive system is the development of 
immunological memory, which allows for a more efficient response upon re-infection. At the 
first encounter of a pathogen, the adaptive immune response requires up to 7 days to form 
an efficient response. During this phase B cells and T cells undergo a strict selection process 
resulting in highly specific cells for that particular triggering threat. After clearance a subset 
of the antigen-specific effector cells will differentiate in long living antigen-specific memory 
cells, which on a re-encounter will directly expand cell number thereby reducing the time to 
form an immune response. Immunological memory is a feature associated with adaptive 
immunity and the formation of long living antigen-specific memory cells (Murphy and 
Weaver, 2017; Natoli and Ostuni, 2019). In recent years the notion that memory is specific for 
adaptive immunity has been challenged as exemplified by memory NK cells  (O’sullivan et al., 
2015).    
 
1.2 T CELLS 
T cells recognize peptides (e.g. antigens) via expression of the highly specific T cell receptor 
(TCR) resulting in their activation (see section 1.2.2 on CD4+ T cell activation). Antigen 
presentation involves cells like APCs to process and present antigens bound to the major 
histocompatibility complex (MHC), forming a peptide/MHC complex.  The MHC class I (MHC-
I) molecule is expressed by most nucleated cells (including APCs) and in humans this class of 
molecules includes human leucocyte antigen A (HLA-A), HLA-B and HLA-C. The MHC class II 
(MHC-II) molecule is restricted to APCs including DCs, macrophages and B cells. In humans 
this group includes HLA-DM, HLA-DOA, HLA-DOB, HLA-DP, HLA-DQ and HLA-DR. The co-
receptors CD4 and CD8 both stabilize the engagement of the TCR with MHC-II and MHC-I 
respectively. T cells are divided into the two major functional classes CD4+ helper T (Th) cells 
and CD8+ cytotoxic T cells (CTL) based on the expression of the co-receptors. CTLs can directly 
kill infected cells by secreting cytotoxic proteins like granzymes and perforin what makes 
them major players in cell-mediated immune response. In contrast, Th cells orchestrate 
immune responses by promoting the activation of various immune cell populations (Kumar 
et al., 2018; Murphy and Weaver, 2017). 
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1.2.1 Thymic development 
T cells are derived from multipotent hematopoietic stem cells that leave the bone marrow 
and migrate to the thymus to form functional albeit not autoreactive T cells (Klein et al., 2014; 
Kurd and Robey, 2016; Takaba and Takayanagi, 2017) (see section 1.3 on Tolerance). In the 
thymic cortex double negative (DN) CD4-CD8- thymocytes differentiate through several stages 
while keeping their DN profile and rearranging their TCRs. The TCR is a heterodimer protein 
consisting of either an alfa and beta chain (abTCR) or gamma and delta chain (gdTCR). The 
TCR is generated through random somatic re-combination of the three gene segments 
encoding it. In principle TCR recombination can give rise to 1015 potential TCRs, however, in 
practice it is estimated that humans have 25 million unique TCRs that are meant to protect 
against an unknown number of adverse antigens (Arstila et al., 2000; Lythe et al., 2016). At 
this stage of their development the majority of thymocytes express an abTCR and a subset of 
T cells will express a gdTCR. gdTCR expressing T cells can be mainly found in mucosal sites.  
During TCR recombination DN thymocytes upregulate both CD4 and CD8 and become double 
positive (DP) CD4+CD8+ thymocytes that further undergo positive selection. DP thymocytes 
bind to self MHC proteins presented by cortical thymic epithelial cells (cTECs) survive the 
positive selection process where DP thymocytes with a too low affinity die from neglect. 
Depending on through which MHC molecule the T cells receive their signal they will either 
commit to become CD4+CD8- or the CD4-CD8+ thymocytes. Positively selected cells will leave 
the cortex for the medulla to undergo negative selection. During TCR re-arrangement a subset 
of T cells are generated that can recognize self-antigens with a too high affinity. The aim of 
negative selection is to eliminate such autoreactive T cells and therefore negative selection 
will shape the TCR repertoire that will leave the thymus. Peripheral tissue antigens (PTA) are 
presented on DCs and medullary thymic epithelial cells (mTECs) The transcription factor AIRE 
(autoimmune regulator) plays a critical role in mTECs differentiation and drives the expression 
of PTAs (Nishikawa et al., 2014; Passos et al., 2018). However, a subset of T cells with relatively 
high affinity to self-antigens will pass negative selection and differentiate into regulatory T 
cells (see section 2.1 on Treg cells development).   
 
1.2.2 T cell activation  
After leaving the thymus naïve T cells circulate the body searching for their TCR specific 
antigen. Unlike some innate immune cells, T cells cannot directly recognize pathogens but 
rely on antigen presentation via the peptide/MHC complex for activation. The adaptive 
immune response is initiated in secondary lymphoid tissues, e.g. lymph nodes, which includes 
the priming of naïve T cells. In short, naïve T cells express the chemokine receptor CCR7 which 
promotes their migration via the blood system to the T cell zones of lymph nodes where 
CCL21, a ligand for CCR7 is produced. DCs from the periphery enter the lymph node where 
they encounter naïve T cells and present their antigens via the peptide/MHC complex, which 
can result in T cell activation. The classical model of T cell activation involves three signals: (I) 
antigen recognition via TCR engagement, (II) co-
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with CD80 and/or CD86 and (III) cytokine signaling through their receptor promoting 
differentiation into the effector cell lineage (see section 1.2.3).  
T cell activation starts with TCR engagement of the peptide/MHC complex. CD8+ CTLs 
normally recognize endogenous peptides presented on MHC-I. However, during the 
activation process CTLs depend on recognizing exogenous peptides presented on MHC-I by 
professional APCs, in a process known as cross-presentation. Since most nucleated cell 
express MHC-I molecules it will later allow the CTLs to directly recognize and kill infected cells. 
CD4+ T cells instead rely on antigen presentation of peptides presented in the context of MHC-
II. In most cases TCR stimulation alone would not be sufficient to initiate activation and T cells 
lacking additional signals would either enter the stage of unresponsiveness, i.e. anergy, or go 
into apoptosis (Kündig et al., 1996). This is exemplified by CD28 knock-out mice that exhibit 
an impaired immune response due to a lack of Th cell activity, however, long term TCR 
signaling might be CD28 independent (Shahinian et al., 1993).    
APCs like DCs express co-stimulatory molecules such as CD80 and/or CD86. Naïve DCs mainly 
express CD86 but upon activation via TLR engagement, DCs start to upregulate both 
molecules that in turn bind CD28 on T-cells providing a stronger second signal (Sansom et al., 
2003). Blocking of this second signal is a well-studied process in immune regulation and opens 
possibilities for clinical intervention.  
The cytokine IL-2 is primarily produced by activated CD4+ T cells and it is often referred to as 
a survival factor of T cells. It binds to the IL-2 receptor resulting in intracellular signaling that 
promotes T cell proliferation. The IL-2 receptor (IL-2R) is a heterotrimeric protein that 
depending on the receptor chains forming it, has a low, intermediate or high binding affinity 
for IL-2. The three receptor chains that exist are CD25, the interleukin-2 receptor chain a (IL-
2Ra), IL-2Rb (CD122) and IL-2Rgc (CD132).  IL-2Rb/gc together have an intermediate affinity 
receptor for IL-2 but both protein chains are not restricted to IL-2R formation. IL-2Rgc is also 
part of the IL-7 receptor, whereas both IL-2Rb/gc are part of the IL-15 receptor. IL-2Ra alone 
has low affinity but in combination with IL-2Rb/gc forms the high affinity IL-2R. CD25 by itself 
is not involved in IL-2 signaling but supports binding of IL-2 where IL-2Rb/gc signaling results 
in activation of pathways involved in cell differentiation, proliferation, survival and activation-
induced cell death (Fontenot et al., 2005). IL-2 signaling also stimulates the upregulation of 
other cytokine receptor chains involved in differentiation of naïve T cells into a different T cell 
subset. This includes IL-12Rb (CD212) and IL-4Ra (CD124) (Liao et al., 2008) and suppressed 
IL-7R-α (CD127) expression (see section 1.2.3 on T cell subsets). Additionally, IL-2 acts in a 
positive feedback loop by stimulating the upregulation of IL-2Ra and IL-2Rb (Liao et al., 2011). 
Taken IL-2 signaling plays a central role in T cell development as well as and maintenance and 
is therefore often referred to as T cell survival factor.  
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1.2.3 T cell subsets and T cell memory 
Antigen recognition and co-stimulation alone can activate naïve T cells and induce cell 
proliferation, however T cell differentiation into T effector (Teff) cells requires additional 
signals provided by cytokines. Depending on the combination of cytokines provided by T cells 
themselves, APCs and other immune cells CD4+ T cells can differentiate into several effector 
Th cell subsets.  
Upon activation naïve CD8+ T cells develop their cytotoxic phenotype that provides them with 
the ability to directly kill infected cells. Naïve CD4+ T cells differentiate into a variety of 
functional different T helper (Th) subsets, depending on the environmental signals they 
receive during T cell activation. The best characterized Th subsets are Th1, Th2, Th17 and 
follicular helper cells. Beside differentiation into Teff cells, naïve T cells can differentiate into 
Treg cells in the presence of TGF-b and IL-2 (discussed in detail in section 2.2).  
In the presence of the cytokines IL-12, IL-18 and IFNg as well as signal transducer and activator 
4 (STAT4) signaling T cells differentiate into Th1. The transcription factor T-bet is the lineage 
defining transcription factor of Th1 cells and Th1 immune responses are aimed towards 
intracellular pathogens (e.g. viruses) and if not controlled properly could result in 
inflammatory diseases. Th2 cells differentiate in the presence of IL-4 and STAT5A signaling 
and IL-2 signaling can enhance IL-4 transcription (Liao et al., 2008). Furthermore, transcription 
factor GATA-3 plays a central role in maintaining Th2 lineage. Th2 cells play a crucial role in 
facilitating an immune response against extracellular pathogens (e.g. parasites) but are also 
associated with allergic inflammation. Th2 signature cytokines include IL-4, IL-5 and IL-15. The 
lineage defining transcription factor for Th17 is retinoic-acid-receptor-related orphan nuclear 
receptor gt (RORgt). Cytokines involved in Th17 differentiation include TGF-b, IL-21 and IL-23 
and intracellular signaling pathways via STAT6 and STAT3. Upon activation Th17 produce 
cytokines including IL-17A, IL-17F and IL-22 that support anti-fungal and anti-bacterial 
immune responses. Miss-managed Th17 responses are associated with autoimmune 
disorders. 
After activation CD4+ Teff cells undergo rapid proliferation during an expansion phase 
followed by a functional phase where they exert their functions. When the initiating factors 
are eliminated the Teff cell pool contracts and a majority of Teff cells undergo apoptosis. The 
CD4+ T cell memory pool is formed during the contraction phase from Teff cells that avoid 
apoptosis. Depending on where these cells persist they are referred to as central memory T 
cells (secondary lymph organs), effector memory T cells (periphery) or tissue-resident 
memory T cells.    
With the advent of fate-mapping animal models and high-throughput sequencing 
technologies like single cell RNA sequencing it became more and more evident that T cells 
display a high plasticity and the concept of true lineage commitment is challenged.   
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1.3 IMMUNOLOGICAL TOLERANCE 
Immunological tolerance is defined as the unresponsiveness of the immune system to 
antigens that were identified as non-dangerous. Depending on the anatomical side where 
tolerance is established, we speak of central or peripheral tolerance. Several key regulators 
for establishing and maintaining tolerance were identified, including FOXP3, cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4) and AIRE (Anderson and Su, 2016; Bluestone, 
1997; Gambineri et al., 2018; Lu et al., 2017).   
At first sight a decreased immune response, or total lack of it, can appear counterintuitive. 
However, the importance of immunological tolerance can be seen when the immune system 
fails to develop tolerance towards certain antigens. Break down of immunological tolerance 
leads to chronic inflammatory responses such as seen in patients with autoimmune diseases. 
Additionally, tolerance against non-harmful environmental and food antigens are critical to 
prevent allergic reactions.  
Central tolerance develops in primary lymph organs. A crucial step in establishing central 
tolerance is the capacity of the immune system to identify self-antigens followed by deletion 
of strongly autoreactive lymphocytes in the thymus and bone marrow during T cell and B cell 
development respectively. Early studies on thymic function revealed that after neonatal 
thymectomy mice develop autoimmune diseases if conducted 3 days after birth. It confirmed 
that cells within the thymus play an important role in immune homeostasis (Gershon and 
Kondo, 1970; Nishizuka and Sakakura, 1969). Later it was found that during T cell 
development the expression of AIRE in mTEC plays a crucial role by regulating the expression 
of tissue specific antigens in the thymus and consequently shaping central tolerance during 
negative selection (see section on thymic development) (Anderson and Su, 2016). In humans, 
mutations in AIRE causes the development of an autoimmune phenotype called autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy (Aaltonen et al., 1997). 
Peripheral tolerance establishes through cells in secondary lymphoid organs, and other 
immunological relevant tissues such as mucosal surfaces in the lung and intestine. There are 
several ways of achieving tolerance in the periphery including induction of anergy and cells 
with immunosuppressive function. Anergy is defined as unresponsiveness to antigenic 
stimulation and occurs when T cells recognize their antigen in the absence of costimulatory 
molecules. Furthermore, in both central and peripheral tolerance a subset of CD4+ T cells, 
called Treg cells, is critical. These cells express two crucial regulators in immunological 
tolerance, the transcription factor FOXP3 and the co-inhibitory receptor CTLA-4  (Taams et al., 
2002) (see section 3 on FOXP3 and section 4.1 on CTLA-4). Both, FOXP3 and CTLA-4 and their 
functional role in Treg cells are topic of this thesis and will be discussed in greater detail below.  
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2 REGULATORY T CELLS 
Treg cells have historically been a controversial topic that fell out of favor in the late 1980s 
(Möller, 1988).  Treg cells then made a reappearance in the mid 1990s when Sakaguchi et al. 
(1995) demonstrated that CD4+CD25+ T cells exhibit a strong suppressive phenotype 
(Sakaguchi et al., 1995) and in the early 21th century the transcription factor FOXP3 
(transcription factor forkhead box P3) was identified as the lineage defining transcription 
factor for cell development and stability (Fontenot et al., 2003; Hori et al., 2003). Treg cells 
are a subset of CD4+ T cells and in humans the frequency of peripheral blood Treg cells varies 
between 5-10 percent out of all CD4+ T cells (Dieckmann et al., 2001).  
In the last two decades several markers were proposed to define Treg cells and these markers 
vary depending on species. The first described marker, CD25, is highly expressed on Treg cells, 
both in human and mice, and is even further upregulated upon TCR stimulation (Baecher-
Allan et al., 2001; Dieckmann et al., 2001; Sakaguchi et al., 1995). In mice, CD25 expression is 
mainly restricted to the Treg cell pool and Treg cells are therefore commonly defined as 
CD4+CD25hi.  Liu et al. showed that CD127, the interleukin-7 receptor α chain (IL-7R-α) is 
negatively associated on human Treg cells (Liu et al., 2006). Therefore, human Treg cells are 
often referred to as CD4+CD25hiCD127lo cells. If restricted to extracellular markers e.g. to 
perform in vitro studies on viable cells, the combination of these three markers is used to 
define Treg cells. Otherwise, FOXP3 expression is used to define Treg cells. In several studies 
it has been shown that FOXP3 expression is highly restricted to the Treg cell pool in mice 
(Fontenot et al., 2005a) but in contrast, human Teff can transiently express FOXP3 upon 
activation in vitro (Walker et al., 2003). It was shown that the Treg cell pool is a heterogeneous 
population and can be further distinguished based on its developmental origin activation 
status and functional activity (see sections below) (Kanamori et al., 2016; Li et al., 2015; 
Richards et al., 2015).   
Furthermore, Treg cells are also characterized by their expression of markers related to their 
functional properties which include CTLA-4, glycoprotein A repetitions predominant (GARP), 
glucocorticoid-induced TNFR-related protein (GITR), inducible T-cell costimulator (ICOS), 
CD37 and CD39 and will be discussed in section 4. Furthermore, markers used to determine 
Treg subpopulations based on activation include CD45RA, CD45RO, CD44, CD62L and CD69 
and will be discussed in section 2.1 (Rosenblum et al., 2016; Sakaguchi et al., 2010). 
 
2.1 TREG CELL DEVELOPMENT AND ACTIVATION 
Treg cells can develop via two distinct routes, either in the thymus alongside with naïve CD4+ 
T cells or in the periphery where they are induced from naïve CD4+ T cells. These two primary 
Treg populations not only differ in their anatomical site of origin but might also play different 
roles in maintaining immune hemostasis and upholding tolerance. Where thymus derived 
Treg (tTreg) cells are described to be more involved in limiting autoimmune responses, 
peripheral induced Treg (pTreg) cells are descripted to be functional more involved at tissue 
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sites exposed to environmental boundaries agents like mucosal tissues (Arpaia et al., 2015; 
Josefowicz et al., 2012; Taams et al., 2002). However, even though different environmental 
signals can induce Treg cell differentiation, in both cases the upregulation and stable 
expression of FOXP3 is seen as the key indicator for Treg cell development (see section 3.1) 
(van Nieuwenhuijze and Liston, 2015). 
With an increase in research on Treg cell biology, several molecules were introduced as 
potential markers to distinguish the tTreg and pTreg populations. First helios and later 
neuropilin-1 were postulated to be expressed by tTreg cells only (Thornton et al., 2010; Weiss 
et al., 2012; Yadav et al., 2012). More recent studies challenged this concept showing that 
that helios as well as neuropilin-1 can be upregulated upon Treg cell activation. (Gottschalk 
et al., 2012; Himmel et al., 2013; Szurek et al., 2015). So far, there is no consensus on what 
combination of markers can be used to define tTreg cell and pTreg cells populations.  
Thymus derived Treg (tTreg) cells split from the conventional T cell lineage during negative 
selection and follow a two-step developmental program (Burchill et al., 2008; Lio and Hsieh, 
2008). When TCR reactivity is tested during negative selection, cells with a higher affinity to 
self-antigens than Tn develop towards the Treg cell lineage (Jordan et al., 2001). Except for a 
small overlap, the TCR repertoire of Treg cells differs from Tn cells and also has greater 
diversity (Hsieh et al., 2004; Pacholczyk and Kern, 2008; Pacholczyk et al., 2006). However, 
the exact selection criteria on TCR reactivity during negative selection is still poorly 
understood.   
Following a two-step developmental program in the thymus, cell differentiation starts with 
TCR stimulation together with CD28 engagement what in turn results in the upregulation of 
proteins supporting Treg cell differentiation including CD25, GITR, CD134 and tumor necrosis 
factor receptor 2 (TNFR2) (Mahmud et al., 2014; Tai et al., 2005; Vang et al., 2010). The 
following step is independent of TCR signaling and instead depends on cytokine signaling. IL-
2 is important for tTreg cell differentiation. Both, il2 deficient and il2ra deficient mice models 
showed the loss of IL-2 signaling reduces tTreg cell output. However, several studies indicated 
that IL-2 signaling can be partly compensated for via IL-15 and IL-7 signaling. Both signaling 
pathways involve receptor complexes that share protein chains with the IL-2R (Bayer et al., 
2008; Fontenot et al., 2005a). Additionally, it was shown that the transcription factor STAT5 
plays an important role during the second phase of tTreg development (Burchill et al., 2007; 
Yao et al., 2007). In a recently published study by Own et al. (2019), the authors postulate that 
tTreg cells can develop via two different developmental programs. In the study two distinct 
Treg precursors were identified, CD25+FOXP3- and CD25-FOXP3lo, that both can develop into 
mature Treg cell in vivo and in vitro. These progenitors differ among other things in their 
affinity to self-peptides, cytokine responsiveness and function (Owen et al., 2019) 
Nevertheless, the exact mechanism during negative selection of self-reactive cells leading to 
the development of tTreg cells rather than apoptosis is still not fully understood  (Richards et 
al., 2015). 
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TGF-b can stimulate the expression of FOXP3 via induction of proteins that in turn promote 
FOXP3 transcription (see section 3.1). TGF-b was shown to support the differentiation of 
peripheral Treg (pTreg) cells from naïve CD4+FoxP3- T cells. Naïve T cells that would go into 
anergy due to an ongoing low TCR stimulation can commit to the Treg cell linage. This stands 
in contrast to tTreg cells, whose differentiation relies on high TCR affinity and the TCR 
remontoir of pTreg cells differs and for example, have TCRs related to the exposure to 
environmental surfaces like commensal bacteria  (Round and Mazmanian, 2010). 
Furthermore, experiments to generate induced Treg (iTreg) cells in vitro showed the 
combination of TGF-b and IL-2 stimulated FOXP3 expression. However, iTreg cells display a 
problem maintaining their FOXP3 expression (Kanamori et al., 2016). 
Similar to effector T cells, TCR stimulation is needed but not sufficient for Treg cell activation.  
An important additional signal is provided by the co-stimulatory receptor CD28 on T cells that 
binds CD80 and CD86 expressed by antigen presenting cells (APC) like dendritic cells (DCs). 
Using Cd28 deficient mice models it was shown that CD28 signaling supports tTreg 
development and upregulation of GITR and CTLA-4, but not complete loss of tTreg (Mahmud 
et al., 2014; Tai et al., 2005; Vang et al., 2010). Furthermore, it was shown that CD28 or 
CD80/CD86 deficiency leads to a reduction in Treg cell numbers that is even more pronounced 
than for Teff cells. Specific CD28 deletion in FoxP3+ Treg cells leads to the development of 
lymphoproliferative diseases (Zhang et al., 2013). 
In effector T cells, CD28 signaling induces IL-2 production but unlike Teff cells, Treg cells 
cannot produce IL-2 themselves (Ono et al., 2007). IL-2, although not absolutely crucial for 
Treg cell development, is important for Treg cell differentiation and maintenance. Germline 
deficient mice either in CD25 or IL-2 show reduced Treg cell numbers (Fontenot et al., 2005a). 
In contrast, mice intravenously treated with IL-2 had increased Treg cell numbers. 
Subsequently, a CD3/CD28 stimulation in combination with recombinant IL-2 is used for Treg 
cell activation in in vitro settings or for ex vivo expansion studies (Hoffmann et al., 2004). 
 
Figure 1: Flow cytometry staining of human PBMCs. (A) The combination of CD45RA and CD25 expression is used to define 
Treg sub-populations. Treg cells in general are higher in their CD25 expression than naïve T cells. (B) To define rTreg and aTreg 
populations first the Treg cells pool is defined as FOXP3hiCD127lo cells (C) followed by gating of CD45RA+FOXP3loCD25++ rTreg 
and CD45RA-FOXP3hiCD25+++ aTreg cells.  
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Miyara et al. (2009) showed the Treg cell pool is not homogeneous rather these cells differ 
phenotypically and functionally. They defined three distinct FOXP3 expressing CD4+ T cells 
groups namely, CD45RA+FOXP3loCD25++ resting Treg (rTreg) cells, CD45RA-FOXP3hiCD25+++ 
activated Treg (aTreg) cells and CD45RA-FOXP3loCD25++ non-Treg cells (see Figure 1) (Miyara 
et al., 2009). CD45RA together with CD45RO are used to distinguish resting from activated 
Treg cells since both proteins are not expressed simultaneously (Booth et al., 2010). rTreg 
cells exhibit suppressive capacities and are able to maintain their FOXP3 expression in vitro 
but in general display a lower expression of functional markers like CTLA-4. Furthermore, they 
are shown to be negative for Ki67 expression and start to proliferate in in vitro cultures upon 
activation. On the other hand, aTreg cell express higher levels of functional markers and are 
Ki67+ but do not proliferate well in vitro and tend to die. Recently, higher CD15s expression 
was introduced as an additional marker to better define aTreg cell populations (Miyara et al., 
2015).   
As mentioned earlier, Teff cells can differentiate into memory T cells. Several groups 
postulated the idea of regulatory T cell memory. However, to classify memory Treg cells based 
on phenotypical and functional markers is challenging. Phenotypically they show a great 
overlap with aTreg cells such as expression of functional markers like CTLA-4 and ICOS. 
Furthermore, it is yet to be seen whether Treg cells survive prolonged periods without TCR 
stimulation which would be a characteristic of memory cells  (Rosenblum et al., 2016). 
Altogether Treg cell development and activation is a multistep process differing between 
pTreg and tTreg cells (Richards et al., 2015). Regardless of which signal cascade stimulates 
Treg cells generation the induction of FoxP3 is crucial.  
 
2.2 LINEAGE STABILITY VS PLASTICITY 
The improvement of omics and other technologies which helps us to study rare cell 
populations has contributed to our understanding of Treg cell biology and it is becoming 
increasingly clear that Treg cells represent a heterogeneous cell population. Several recent 
studies suggest that Treg cells display a higher plasticity than initially thought but it is still 
under debate if this might include either lineage plasticity or functional plasticity or even both.  
FOXP3 stability is in the center of this discussion since it was seen that FOXP3 is a key regulator 
in Treg cell biology and induction and maintaining of FOXP3 expression is regulated separately 
(Zheng et al., 2010). It was shown that Treg cells can maintain their suppressive phenotype 
and FOXP3 expression while proliferating and expanding. Furthermore, studies on epigenetic 
control linked the de-methylation of the FOXP3 promotor region with a stable expression of 
FOXP3 in Treg cells (Floess et al., 2007; Kim and Leonard, 2007). Rubtsov et al. (2010) studied 
Treg cell plasticity using a Treg cell fate mapping mouse model (Foxp3GFP-Cre-ERT2 knock-in 
ROSA26YFP mice) and found that during both homeostasis and inflammation Treg cells remain 
stable indicating that tTreg cells might be more stable than pTreg cells (Rubtsov et al., 2010). 
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Furthermore, it was shown that pTreg cells might be epigenetically less stable in respect to 
their FOXP3 expression (Polansky et al., 2008). 
In contrast, in several studies it was shown that Treg cells may lose their FOXP3 expression in 
pro-inflammatory environments and develop a more effector Th cell phenotype in response 
to certain environmental signals. It was reported that Treg cells can start to produce effector 
cytokines like IL-2 and IL-17 (Duarte et al., 2009; Yang et al., 2008). Furthermore, Teff cells can 
transiently express FOXP3 (see section 3) and recent studies showed FOXP3 expressing Teff 
cells can potentially differentiate into Th17 cells in the presence of IL-1b (Mailer et al., 2015). 
Treg cell plasticity towards the Th17 phenotype was also described in rheumatoid arthritis 
mice models where the authors showed that Th17 can develop from FOXP3+CD25lo cells 
(Komatsu et al., 2014). It was also shown that Treg cells differentiate at different anatomical 
sites. The existence of tissue specific Treg cells indicates Treg cells can be influenced by their 
environment. However, the lack of markers to distinguish tTreg and pTreg cell populations 
makes it challenging to address the question if observed lineage plasticity is due to the pTreg 
cells (Polansky et al., 2008).   
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3 FOXP3 
FOXP3 is a forkhead/winged-helix transcription factor that confers its function by binding DNA 
as part of a multi-protein complex to activate or repress transcription. FOXP3 was linked to 
immune regulation in the early 2000s when it became evident that a frame-shift mutation of 
FOXP3 was responsible for the lymphoproliferative disease of scurfy mice (Bennett et al., 
2001; Brunkow et al., 2001). In 2003 three research groups demonstrated FOXP3 was the 
master regulator for Treg cell development. More recent studies suggest FOXP3 expression 
does not automatically indicate functional Treg cells (Tran et al., 2007). Human effector T cells 
can transiently express FOXP3 without being immune suppressive (Allan et al., 2007; Miyara 
et al., 2009). 
 
3.1 FOXP3 GENE STRUCTURE AND EXPRESSION  
In both, human and mice, the FOXP3 gene is located on the X-chromosome and consists of 
eleven coding exons (1 - 11) and three non-coding exons (-2a to -1). The eleven coding exons 
encode four protein domains. Exon 1 to 4 encode the repressor domain, exons 5 and part of 
6 the zinc finger domain, the other part of exon 6 together with exon 7 encode for the leucine 
zipper and exon 9 to part of 11 the forkhead (FKH) domain (Figure 2). Exons 2 and 7 are both 
simultaneously and separately alternatively spliced (see section 3.3 on FOXP3 isoforms). 
FOXP3 expression is regulated by the FOXP3 promoter together with three enhancers 
(conserved non-coding sequences, CNS). FOXP3 expression is strongly related to Treg cell 
differentiation and activation and relies on similar pathways namely TCR signaling, co-
stimulation and cytokine signaling (Figure 3) (Huehn and Beyer, 2015; Huehn et al., 2009; 
Kitagawa et al., 2015b; 2015a).  
Besides the FOXP3 promotor, the three non-coding sequence regions CNS1, 2 and 3, all 
interact with different proteins and are involved both in initiation and maintenance of FOXP3 
expression but differ in respect to which phases of Treg cell development they are involved 
in. CNS3 was described to initiate FOXP3 expression and binding of c-Rel to CSN3 was 
described to be crucial for tTreg development (Ruan et al., 2009). CNS2 is a CpG-rich sequence 
enhancing and stabilizing the expression of FOXP3 (Polansky et al., 2008). It is the site of 
epigenetic control of FOXP3 expression and de-methylation stabilizes FOXP3 expression. 
CNS2 is also referred to as Treg-cell specific de-methylated region (TSDR) and in Teff cells this 
specific region is methylated. Furthermore, several transcription factor binding sites were 
described in CNS2, including GATA3, ETS1 and FOXP3 itself. The deletion of CNS2 results in a 
gradual loss of FoxP3 in mice (Ogawa et al., 2014; Zheng et al., 2010). FOXP3 expression 
regulation via CSN1 is associated with pTreg development. TGF-β signaling promotes FOXP3 
expression by upregulating the transcription factors Smad3 which acts via binding to the CNS1 
region (Schlenner et al., 2012; Zheng et al., 2010). 
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Furthermore, TCR signaling and co-stimulatory signaling trough CD28 both upregulate FOXP3 
expression (Salomon et al., 2000; Tai et al., 2005). TCR signaling results in binding of NFAT 
(nuclear factor of activated T cells) and AP1 (activator protein 1) which both induce FOXP3 
expression by binding to its promotor and CNS1 (Mantel et al., 2006). Interestingly, expression 
of NFAT in conjunction with RUNX1 and FOXP3 leads to a reduction in Treg function (Ono et 
Figure 2: Schematic representation of the FOXP3 gene and protein. FOXP3 gene consist of three non-coding exons (-2a, -
2b and -1) has three conserved no-coding sequences (CNS1, CNS2 and CNS3) and eleven exons (1 - 11). Exon 1 to 11 encodes 
for the four functional regions, three repressor domain, zinc finger, leucine zipper and the Forkhead DNA-binding domain.  
Figure 3: FOXP3 expression in CD4+ T cells. A combination of TCR, co-stimulatory and cytokine signaling induced FOXP3 
expression. Both the FOXP3 promotor and CNS regulate transcription via interacting with different proteins. Adapted from 
(Nie et al., 2015) 
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al., 2007; Wu et al., 2006). In the thymus CD28 stimulation was seen to induce FOXP3 
expression (Tai et al., 2005) but strong CD28 signaling in the periphery was shown to 
negatively regulate FOXP3 expression. The IL-2 signaling cascade involves Janus kinase 1 
(JAK1) and JAK3 and the signal STAT5. STAT5 in turns binds the FOXP3 promotor as well as 
CNS2 leading to increased FOXP3 expression and stabilization.  
 
3.2 FOXP3 PROTEIN STRUCTURE AND FUNCTION 
FOXP3 consists of four domains, namely the repressor domain at the N-terminal end of the 
protein, followed by the zinc finger domain, the Leucine zipper domain and the Forkhead DNA 
binding (FKH) domain at the C-terminal end (Figure 2). Treg cells express a distinct set of 
differentially regulated genes in comparison to effector T cells. It has been shown that FOXP3 
is able to control expression of around half of these genes and FOXP3 is described to work 
both as a suppressor and activator of mRNA translation. Genome-wide studies revealed that 
FOXP3 in collaboration with other proteins control over 700 genes but only a fraction of these 
genes is directly controlled by FOXP3 binding. (Marson et al., 2007; Zheng et al., 2007). So far, 
over 360 proteins, including other transcription factors, were reported to interact with FOXP3 
and act in protein complexes to regulate transcription  (Hori, 2012; Lozano et al., 2013; Rudra 
et al., 2012; Sadlon et al., 2010). 
The N-terminal repressor domain contributes to the suppressive activity of Treg cells. This 
FOXP3 domain mediates gene expression by interacting with transcriptional activators and 
repressors. For example, FOXP3 interacts with members of the NF-kB family proteins known 
to be responsible for a variety of pro-inflammatory cytokine up-regulation (Bettelli et al., 
2005; Deng et al., 2012; Lopes et al., 2006), Furthermore, it was reported transcription factors 
of the ROR family, RORa and RORgt, bind to motifs expressed by exon 2 leading to suppression 
of Th17 differentiation (Ichiyama et al., 2008; Zhou et al., 2008). Also, STAT3 interacts with 
FOXP3 by binding to the repressor domain. The function of the zinc finger domain remains 
unclear. FOXP3 requires dimerization via the leucine zipper domain to bind to DNA (Chae et 
al., 2006). Beside binding to itself, FOXP3 also binds other proteins like FOXO1 via the leucine 
zipper domain to regulate additional aspects of FOXP3 functions. Treg cells is regulated via 
this domain. FOXP3 binds to DNA via its FKH domain via the GTAAACA motive (Koh et al., 
2009). Furthermore, some of Treg cells most important regulatory mechanism are controls 
via this domain. For example, FOXP3 DNA binding is associated with the repression of IL-2 and 
the expression of CD25 and CTLA-4 (Hill et al., 2007; Marson et al., 2007; Ono et al., 2007).   
 
3.3 FOXP3 ISOFORMS 
The foxp3 gene consists of eleven coding exons and when fully transcribed form the full-
length isoform of FOXP3, FOXP3fl. In human, three additional isoforms that are the result of 
alternative splicing of exon 2 and/or exon 7 were identified. Alternative splicing of the two 
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exons give rise to the isoforms lacking either exon 2 (FOXP3D2) or exon 7 (FOXP3D7). 
Additionally, alternative splicing of both regions results in the so called FOXP3D2D7 (Kaur et 
al., 2010; Mailer et al., 2009; Smith et al., 2006; Walker et al., 2003). FOXP3 isoforms differ in 
their molecular weight, where FOXP3fl has the highest weight with 47 kDa, followed by 
FOXP3D7 with 44 kDa, FOXP3D2 with 43 kDa, and FOXP3D2D7 with 40 kDa. The molecular 
weight of both FOXP3D2 and FOXP3D7 is challenging to distinguish using techniques like 
western blot.  
FOXP3fl and FOXP3D2 are the predominant FOXP3 isoforms and both are simultaneously 
expressed by Treg cells and contribute to the suppressive function of Treg cells. Exon 2 
encodes a part of the repressor domain that, as mentioned above, is involved in the 
interaction with protein binding partners. Therefore, it can be assumed that alternative 
splicing of this region has an effect on FOXP3 to form protein complexes. For example, it was 
shown that exon 2 encodes for a binding site for transcription factors of the ROR family and 
as a result suppress IL-17A (Du et al., 2008). In turn, RORγt is a regulator of Th17 
differentiation indicating the importance of the repressor domain in balancing differentiation 
between Treg cells and Th17 cells. 
Our group has recently described a role for FOXP3 isoforms in regulating T cell differentiation 
between Treg cells and Th17 cells. In brief, IL-1β favors Th17 differentiation in vitro by 
promoting FOXP3Δ2Δ7. Also, we observed a correlation between FOXP3 lacking exon 7 
variant expression and clinical score in biopsies of Crohn´s disease patients (Mailer et al., 
2015). In contrast to Foxp3fl and Foxp3D2, Foxp3D2D7 does not contribute to the suppressive 
ability of Treg cells.  Exon 7 encodes part of the leucine zipper and deletion of exon 7 is likely 
to interfere with the dimerization of FOXP3. In a study published 2015, we generated mice 
expressing the murine equivalent of Foxp3 lacking exon 2 and 7 (Foxp3d2d7) only. Males 
developed a phenotype similar to scurfy mice. This suggests that Foxp3d2d7 does not confer 
a suppressive function of Treg cells in vivo (Joly et al., 2015). Expression of FOXP3D7 was 
detected in human T cells using qPCR but so far it is unclear how its function differs from the 
other three isoforms (Kaur et al., 2010) Since FOXP3D7 is lacking part of the leucin zipper 
domain that takes part of the dimerization of FOXP3 protein it might lack the ability to support 
Treg cell suppressive function.  This is supported by the finding of an IPEX patient with a 
mutation that excludes exon 7 from the protein. 
The exact signals activating alternative splicing and the mechanism by which it is regulated 
remain poorly understood. Also, little is known regarding the differences in protein function 
and capacity of interaction with co-factors of the different isoforms. Studying FOXP3 isoforms 
can be challenging with commonly used methods in immunology research that depend on 
the use of antibodies, including flow cytometry and SDS-PAGE.  
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3.4 FOXP3 MUTATIONS (IPEX) 
Both, IPEX syndrome in humans and the scurfy phenotype in mice are the result of mutations 
in the FoxP3 gene. Scurfy mice were first described in the late 1950s and characterized as a 
spontaneous, recessive X-linked mutation. First symptoms in affected mice start to show at 
around 2 weeks of age as reddening and swelling of outer genitalia shortly after followed by 
ruffled, scaly skin of e.g. ears, tail and eyelids. In general, these animals are smaller, display a 
hunched posture and the majority of scurfy mice died at around 3 weeks of age (before 40 
days). In the early 1990s the immune phenotype of scurfy mice was characterized as a 
lymphoproliferative disease. Animals have an enlarged liver, spleen and LNs including 
immune cell infiltration. Additional, scurfy mice have elevated IgG levels (Godfrey et al., 
1991a; 1991b). The scurfy phenotype was later linked to a 2-base pair insertion in exon 8 of 
the Foxp3 gene resulting in a loss-of-function mutation in the FOXP3 protein  (Brunkow et al., 
2001).  
In human, mutations on any of the regions of the FOXP3 gene is linked to the development of 
IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked), a syndrome 
characterized by the development of multiple autoimmune disorders with an onset typically 
within the first few months of life (Bennett et al., 2001; Chatila et al., 2000). IPEX is a rare X-
linked disease with an estimated prevalence of 1 in 1.6x106. Onset and severity vary between 
affected individuals but common clinical phenotypes include autoimmune enteropathy, 
dermatitis and poly-endocrinopathy including type 1 diabetes. Table 1 summarized most 
common symptoms of IPEX patients (Gambineri et al., 2018; Wildin et al., 2001). More recent 
studies also indicate a correlation between IPEX and miscarriage (Reichert et al., 2016; Xavier-
da-Silva et al., 2015). Treatment of IPEX depends on the individual manifestation and ranges 
from symptom specific treatments (e.g. insulin in case of type 1 diabetes) over immune 
suppressive drugs, to bone marrow transplantation in severe cases  (Gambineri et al., 2018). 
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Table 1: Overview of IPEX symptoms. IPEX is an autoimmune phenotype in humans carrying mutations in the Foxp3 gene. 
Clinical manifestation varies between patients and this table summarized frequencies of disease associated symptoms   
(Gambineri et al., 2018). 
Symptom Frequency   
Enteropathy 97% 
Watery diarrhea (minority blood/mucus), Atrophy on small 
bowel (45%) 
 36% Severe food allergy 
Skin Disease 89% 
Eczema and/or exfoliative (85%), Erythroderma (8%), 
childhood alopecia (11%) 
Endocrinopathy 65% 
Type I diabetes mellitus (49%, mean onset 27 month), 
hypo/hyperthyroidism (26%), adrenal insufficiency 
Serious Infections 47% 
sepsis, meningitis, peritonitis, pneumonia 
Staphylococcus (23%), Cytomegalovirus (10%), Candida 
(19%) 
Hematologic disease 42% 
Anemia (33%), neutropenia (13%), thrombocytopenia 
(22%), Organ /non-organ specific autoantibodies (17%) 
Renal 28% 
Autoimmune hepatitis (20%), glomerulonephritis, 
interstitial nephritis, unexplained hypertension, persistent 
hematuria, proteinuria, 
Neurologic 24% 
seizure disorders (14%), ventriculomegaly (3%), 
developmental delay (14%; higher than in other cohorts) 
Pulmonary 23% 
Asthma & interstitial lung disease (23%), lymphadenopathy 
(14%), lymphadenopathy (3%) 
Hepatic 20%  
Arthritis/Vasculitis 9%   
Lymphadenopathy 14%  
Cardiovascular 2% 
pericarditis, atrial flutter, dilated aortic root, pericardial 
effusion, and aneurisms 
Failure to thrive 75%   
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4 TREG CELL EFFECTOR FUNCTION 
Treg cells are important for maintaining immune homeostasis, tolerance and control normal 
immune responses, due to their capacity to suppress a large number of immune cells, 
including T cells, DCs and NK cells (Levings et al., 2001). However, this ability also makes their 
malfunction susceptible to contribute to the development of autoimmune disorders. 
Furthermore, Treg cells are often associated with worse cancer prognosis (see section 5). In 
recent years, different mechanisms were postulated regarding how Treg cells execute their 
suppressive role. A wide repertoire of suppressive mechanisms ranging from cell-cell contact 
depending to cytokine-mediated suppression were described (Figure 4) (Vignali et al., 2008; 
Walker and Sansom, 2011). One drawback in studying suppressive function of human Treg 
cells is that research is often restricted to in vitro assays. Furthermore, most in vivo data are 
based on animal models.  
One key role of Treg-mediated suppression is their ability to control the T cell pool by either 
directly interfering with T cell function or in a more indirect way via APC suppression. As 
discussed above Treg cells follow a similar path for cell activation as other CD4+ T cells, 
including their need for IL-2. Since Treg cells do not produce IL-2 themselves, they rely on IL-
2 produced in their environment. A mechanism referred to as IL-2 deprivation was postulated 
by which Treg cells starve IL-2 dependent cells, including Teff cells, from IL-2 due to their 
continuously high expression of CD25 (Thornton and Shevach, 1998). However, IL-2 
deprivation was shown in vitro and data that prove this concept in vivo are limited and 
complete IL-2 knockout mice die from a CD4+ T cell driven lymphoproliferative disease. Thus, 
it is not obvious to envision how IL-2 deprivation would function as a specific pathway to 
immunosuppression in vivo (Pandiyan et al., 2007).  
Another mechanism of Treg-mediated-suppression of Teff cell activity is by co-expressing the 
extracellular nucleotidases (ectoenzymes) CD39 and CD73. CD39/CD73 converts ATP 
(adenosine triphosphate) to adenosine and thereby increasing pericellular adenosine which 
in turn generates an immunosuppressive environment for Teff cells due to their expression 
of the adenosine A2A receptor (Deaglio et al., 2007; Kobie et al., 2006; Dwyer et al., 2007; 
Zarek et al., 2008). Lately, the use of blocking antibodies against CD39/CD73 came into focus 
as a way to improve anti-cancer responses (Perrot et al., 2019).  
Treg cells are also known to secrete anti-inflammatory cytokines, like IL-35, IL-10 and TGF-b. 
IL-10 is a known anti-inflammatory cytokine, that beside T cells is produced also by B cells and 
monocytes. The actual contribution of IL-10 to Treg suppressive functions is still unclear 
(Asseman et al., 1999; Hara et al., 2001; Rubtsov et al., 2008). Beside the role of IL-10 in Treg 
development, TGF-b production is also described as an effector function of Treg cells but 
similar to IL-10 its contribution and functional mechanism are unclear. However, in vitro 
assays the physical separation of Treg cells and responder cells results in reduced suppression 
and neither IL-10 or TGF-b knock out mice develop an autoimmune phenotype. Nevertheless, 
in Treg cells from IL-35 knock out models display a reduced functionality. And IL-35 alone 
shows the capacity to suppress T cell proliferation in vitro.  
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Another well studied mechanism how Treg cells can control Teff cells is by controlling Tn cell 
activation via the suppression of DCs. It is known from in vitro assays that DCs show decreased 
levels of CD80 and CD86 expression in the presence of Treg cells and these suppressed DCs 
are less capable to support T cell proliferation (Cederbom et al., 2000; Tang et al., 2006). 
Furthermore, it was shown that Treg cells interact with DCs in vivo. In the case of Treg-
mediated suppression of DCs several mechanisms are described, including via the expression 
of CTLA-4, Lag-3 and Nrp-1 and induction of IDO in DCs. The enzyme Indoleamine 2,3-
dioxygenase (IDO) turns tryptophan to kynurenine. The depletion of tryptophan from the 
environment inhibits Teff cell activation and proliferation.  The induction of IDO expression in 
DCs was shown to be associated with CTLA-4 engagement with CD80 and CD86.  
Beside CTLA-4 Treg cells express additional immune checkpoint molecules like programmed 
cell death protein 1 (PD-1), ICOS and Lag-3. PD-1 molecule is mainly expressed on B cells and 
T cells, including Treg cells, and belongs to the same superfamily as CD28, ICOS and CTLA-4 
(Chamoto et al., 2017; Yamazaki et al., 2002). PD1 ligands include programmed cell death 
ligand 1 and 2 (PD-L1 and PD-L2) and are both expressed by a variety of immune cells, 
including DCs. Additionally PD-L1 can be also found on non-hematopoietic cells (Chamoto et 
al., 2017; Yamazaki et al., 2002a). More recent studies also indicated that PD-1 might interact 
with CD28 on CTLs. PD-1 ligand binding results in the blocking of the signaling cascade 
Figure 4: Treg cell mediated suppresser function. Treg cells exhibit a variation of effector functions ranging from secretion of 
anti-inflammatory cytokines, expression of checkpoint inhibition molecules and metabolic disruption. Target cells for Treg 
mediated suppression includes Teff cells and DCs. (Ohue and Nishikawa, 2019)  
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downstream of TCR by e.g. intervening with PI3K signaling. Furthermore, PD-1 expression on 
T cells is also associated with cell exhaustion (Chamoto et al., 2017; Liang et al., 2006; Okazaki 
et al., 2011). 
 
4.1 CTLA-4 (CD152) 
In humans, the gene encoding CTLA-4 is located on chromosome 2q33 downstream of CD28, 
whereas in mice it is located on chromosome 1  (Brunet et al., 1987; Naluai et al., 2000). CTLA-
4 is a structural homologue to CD28 that encodes both a binding domain for the co-
stimulatory molecules CD80 and CD86 expressed on APCs and CTLA-4 binds with a ~20 fold 
higher affinity to CD80 than CD28. Both molecules belong to the same immunoglobulin family 
but CD28 functions as a co-stimulatory receptor whereas CTLA-4 is a negative modulator in T 
cell activation (Brunet et al., 1987; Freeman et al., 1991; Harper et al., 1991; Linsley et al., 
1991b; 1991a; van der Merwe et al., 1997; Rudd et al., 2009; Tivol et al., 1995; Walunas et al., 
1994; Waterhouse et al., 1995). CTLA-4 is a homodimer mainly expressed on CD4+ and CD8+ 
T cells. But several studies indicated that CTLA-4 can be expressed by APCs including B cells 
and potentially DCs. The functional role and general expression pattern in these cells still 
needs to be studied in greater detail (Brunet et al., 1987; Oaks et al., 2000; Quandt et al., 
2007; Wang et al., 2011). In contrast, CTLA-4 expression in T cells and in particular Treg cells, 
is a well-established feature and is associated with Treg cell suppressive function. CTLA-4 is 
constitutively expressed on Treg cells in a FoxP3-dependent manner and its expression is 
rapidly further upregulated upon cell activation. Similarly, Teff cells start to upregulate CTLA-
4 expression upon TCR stimulation but it is not expressed in naïve T cells (Miyara et al., 2009; 
Rudd et al., 2009; Takahashi et al., 2000). In T cells, CTLA-4 accumulates, if expressed 
extracellular, in the immune synapse but the majority is stored intracellular (in endosomes) 
and therefore can be rapidly upregulated. CTLA-4 can be re-cycled in cells and after 
internalization via endocytosis it is either stored and re-expressed or undergoes degradation 
in lysosomes.  In recent studies it was shown that the protein LRBA (lipopolysaccharide-
responsive and beige-like anchor protein) is heavily involved in recycling of CTLA-4 (Hou et al., 
2017).  Just as CTLA-4, CD28 also undergoes endocytosis and binding of PI-3K to the 
cytoplasmic tail of CD28 is involved in this process. Similarly, CD28 either re-cycles back to the 
cell surface or undergoes degradation (Céfaï et al., 1998). 
The CTLA-4 protein consists of four functional domains encoded by four exons. The 
extracellular part consists of a leader peptide (encoded by exon 1) and a ligand-binding 
domain (exon 2), followed by a transmembrane domain (exon 3) and finally, the cytoplasmic 
tail (exon 4) that is part of the intracellular domain (Brunet et al., 1987; Ling et al., 1999). In 
mice, four isoforms were identified that are results of alternative splicing: a full length from 
of CTLA-4 (flCTLA-4), a ligand independent form lacking exon 2 (liCTLA-4), a soluble isoform 
lacking exon 3 (sCTLA-4) and a isoform lacking both exon 2 and 3 (1/4CTLA-4) (Figure 5). In 
humans, the liCTLA-4 isoform is not described (Huurman et al., 2007; Oaks et al., 2000; Ueda 
et al., 2003).  
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In a study done by Oaks et al. (2000) it was shown 
that sCTLA-4 is conserved between mouse, rat 
and humans. mRNA expression levels for sCTLA-4 
vary between immune cells (CD4+ T cells 
expressing the highest levels), cell activation 
(resting cells express pre-dominant sCTLA-4) and 
location (present in blood serum but not in 
thymus) (Oaks et al., 2000) and over-expresion of 
sCTLA-4 was linked to several autoimmune 
disorders (Pesce et al., 2014; Saverino et al., 
2010; Simone et al., 2014). In respect to 1/4CTLA-
4 little is known about its function in a normal 
immune setting but in several studies, it was 
shown that 1/4CTLA-4 is over expressed in 
autoimmune patients (Ichinose et al., 2013; Liu et 
al., 2012). The liCTLA-4 isoform is the only one not described in human. In a diabetes mouse 
model it was shown that liCTLA is a naturally occurring isoform in peripheral T cells and has 
an enhanced expression on memory cells. Furthermore, this study suggests that liCTLA-4 plays 
a role in preventing T cell mediated autoimmunity. Furthermore, in a study done on mice 
charring an artificial mutation in the exon 2 region of CTLA-4 showed a loss of the binding 
capacity does not result in a lymphoproliferative phenotype in these mice. Additionally, they 
saw that CTLA-4 mediated suppression of T cell activity was not impaired  (Chikuma et al., 
2005; Stumpf et al., 2013; Vijayakrishnan et al., 2004). 
Figure 5: CTLA-4 isoforms. CTLA is encoded by four 
exons that each in itself encodes one functional domain. 
All exons can be alternatively spliced what gives rise to 
four different isoforms.  
Figure 6: CTLA-4 signaling. Several mechanism of function were descripted for CTLA-4 ranging from cell intrinsic pathways to 
cell-extrinsic pathways.   
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The importance of CTLA-4 to control immune tolerance and maintain immune homeostasis is 
well established. In independent studies done on knock-out mice models it was shown that 
CTLA-4 deficiency leads to the development of an autoimmune phenotype similar to the 
scurfy phenotype. For example, germline CTLA-4 deficient mice died within 3 to 4 weeks after 
birth caused by lymphoproliferative disorders. (Chambers et al., 1997; Tai et al., 2007; Tivol 
et al., 1995; Waterhouse et al., 1995). Furthermore, Wing et al. (2008) studied the effect of 
CTLA-4 deletion in CD4+FOXP3+ Treg cells by creating a Cre-conditional CTLA-4 knock out 
strain under the FOXP3 promotor. When compared to complete CTLA-4-/- mice, the 
conditional knock-out mice still develop a lymphoproliferative diseases phenotype but at a 
slower progression rate. Furthermore, Treg cells lacking CTLA-4 showed an impaired function 
in controlling CD80 and CD86 expression of DCs in vitro (Wing et al., 2008). In contrast, in 
conditionally ablated CTLA-4 during adulthood in CD4+ T cells, mice did not develop a fatal 
phenotype as seen in the germline deletion models. Nevertheless, histological data revealed 
pathological inflammatory changes in several tissues including insulitis and gastritis (Klocke et 
al., 2016; Paterson et al., 2015). A comparable situation was described in humans where 
polymorphisms in the CTLA-4 gene were correlated with different autoimmune and 
inflammatory diseases. 
Taken together these findings indicate that CTLA-4 is a major player in maintaining immune 
hemostasis and tolerance by controlling T cell proliferation. But until today it is still 
controversial how CTLA-4 functions and signals. Several models for CTLA-4-mediated 
suppression were postulated that can be divided into cell-intrinsic pathways and cell-extrinsic 
pathways (Figure 6). When it comes to CTLA-4 mediated suppression Treg cells due to their 
constitutively high expression, however since effector T cells express CTLA-4 as well they can 
contribute to CTLA-4 mediated suppression. 
Several mechanisms were postulated in respect to cell-intrinsic suppression of CTLA-4 that 
could directly affect Treg cell function. It was shown that the cytoplasmic tail of CTLA-4 is not 
only involved in recycling of the protein but also in receptor signaling. Protein kinase C was 
shown to interact with the cytoplasmic tail, an interaction that supports Treg cell suppressive 
activity (Choi et al., 2006; Kong et al., 2014; Stumpf et al., 2014). Since CTLA-4 and CD28 are 
simultaneously expressed in the same cell, CTLA-4 could potentially outcompete CD28 
signaling on the same cell.  
Cell-extrinsic pathways focus on CTLA-4-dependent suppression of APCs. This includes IDO 
induction, secretion of inhibitory cytokines and controlling availability of CD80/CD86, all 
mechanisms are potentially Treg-mediated. In recent years, Treg cell-mediated inhibition of 
DCs gained more interest as it was discovered that Treg cells and DCs interact in vivo. DCs are 
known to promote T cell priming and differentiation, thus DC suppression could be one 
mechanism of Treg cells to indirectly control effector T cells in vivo (Tang et al., 2006). 
Moreover, it was shown that Treg cells can control CD80 and CD86 expression on DCs in both 
human and mice but these are mainly in vitro observations (Cederbom et al., 2000; Mavin et 
al., 2017; Misra et al., 2004; Onishi et al., 2008). Until now it stays unclear whether Treg cells 
actively downregulate CD80/CD86 or rather interfere with DC maturation. Several 
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mechanisms were proposed on how CTLA-4 controls CD80/CD86 availability during naïve T 
cell priming. Since CTLA-4 binds with a stronger affinity than CD28 and is highly expressed on 
Treg cells it was theorized that CTLA-4 simply outcompetes CD28 and thereby reducing co-
stimulatory signaling. Another model that gained great popularity among researchers 
supports the hypothesis that the engagement of the ligand-binding domain of CTLA-4 with 
CD80/CD86 results in the physical removal of the receptors from the DC membrane in a 
process called transendocytosis (Hou et al., 2015; Qureshi et al., 2011; Walker and Sansom, 
2011). Qureshi et al. (2011) introduced the concept of transendocytosis in the setting of CTLA-
4 function. In an in vitro assay they demonstrated that CTLA-4–expressing CHO cells were 
capable of removing and internalize CD86 from CD86–expressing CHO cells. They furthermore 
demonstrated in a co—culture assay of MDDCs with activated human CD4+CD25- cells that 
CD86 was reduced on MDDCs and was found intracellular of activate T cells, a process that 
could be blocked by the use of anti CTLA-4 blocking antibody  (Qureshi et al., 2011). 
Regardless of cell-intrinsic or extrinsic pathways, what most of these mechanisms have in 
common is, that the engagement of the ligand-binding domain with CD80/CD86 is the cause 
of the signaling. The two isoforms 1/4CTLA-4 and liCTLA-4 lack the ligand-binding domain and 
until today their role is mainly discussed in pathological situations which warrants further 
study. 
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5 TREG CELLS IN DISEASE 
Immunity regulates and contributes to most of today’s major diseases. Thus, it is not 
surprising that a cell population, like Treg cells, that controls the magnitude of immune 
responses alter disease outcome in a wide variety of diseases.  In autoimmune disorders Treg 
cells are seen to have a decreased capacity to suppress due to impaired function or numbers 
(Dominguez-Villar and Hafler, 2018). This reflects a setting where functional Treg cells are 
beneficial for the patient. On the other hand, in tumor biology the presence of Treg cells often 
predicts a poor prognosis. Even if this “either-or” picture reflects a simplified version of Treg 
cells function it still gives us an idea how Treg cell biology affects such a broad range of disease 
processes.   
Many studies showed cancer is an umbrella term for a set of diseases that have the formation 
of tumor cells in common but are diverse in their cause, progression and treatment. Six 
hallmarks of cancer biology were originally postulated that characterize cancer cells: 
sustaining proliferation, evasion of growth suppression, invasion and metastasis, replicative 
immortality, induction of angiogenesis and resistance to cell death. Additionally, based on 
studies from the last two decades additional hallmarks (deregulation of cellular energetics 
and avoiding immune destruction) and enabling characteristics were added (tumor-
promoting inflammation and genomic instability and mutations) (Hanahan and Weinberg, 
2011) In respect to the immune system, it was shown that an inflammatory environment 
contributes to the development and progression of cancer and that tumor cells can develop 
a large repertoire of mechanisms to manipulate immune responses in their favor (Grivennikov 
et al., 2010). This includes the recruitment of suppressor cells like Treg cells and myeloid-
derived suppressor cells (Gabrilovich and Nagaraj, 2009; Liu et al., 2016; Ohue and Nishikawa, 
2019).  
A large number of experimental studies have demonstrated that Treg cells inhibit anti-tumor 
immune responses (Onizuka et al., 1999; Teng et al., 2010). deLeeuw and colleagues recently 
reviewed 58 clinical studies and determined that Treg cells correlated with a negative 
prognosis in 23 studies, with a neutral prognosis in 23 studies and good prognosis in 12 studies 
(deLeeuw et al., 2012). Hence it seems that Treg cells play a two-faced role in anti-tumor 
responses. This might be explained by several things. It can be difficult to truly distinguish 
Treg cells from Teff since Teff cells are seen to transiently express FOXP3 in such highly 
activated environments and Treg cells are described to be a heterogeneous population, hence 
their functional state and stability might be more important than looking at total Treg cell 
number. Treg cells can also be suppressive towards other anti-tumor immune cells and 
thereby contribute to an immune suppressive tumor micro-environment (Whiteside, 2008). 
However, Treg cells can also suppress tumor promoting factors such as chronic inflammation 
as well as tumor invasiveness (Winerdal et al., 2018). 
In the last couple of years immune check point inhibition showed to be a novel approach in 
treating a variety of cancer types (Anderson and Rapoport, 2018; Byun et al., 2017; Chamoto 
et al., 2017; de Coaña et al., 2015). Blocking antibodies against both PD-1 (Nivolumab) and 
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CTLA-4 (Ipilimumab) were approved for clinical use to target Treg cell function. Ipilimumab 
immune therapy showed promising results in some tumor settings but failed in others. In 
metastatic melanoma patients Ipilimumab alone was shown to lead to an enhanced overall 
survival. However, especially the combined usage of both anti-PD-1 and anti-CTLA-4 is 
promising (Curran et al., 2010). Nevertheless, immune check point inhibition comes with the 
risk of severe site effects in e.g. the liver, skin, and gut. This indicates how important it is to 
gain a better understanding in CTLA-4 signaling.  
As seen in IPEX patients, the loss of Treg cells results in the development of a range of 
autoimmune diseases due to break of immune tolerance. This in turn results in an 
inappropriate reaction of the immune system to self-antigens and the development of chronic 
inflammation. Autoimmune diseases range from tissue specific disorders like type 1 diabetes 
and multiple sclerosis, systemic disorders like systemic lupus erythematosus (Miyara et al., 
2011). In respect to Treg cells, defects in either cell frequency or function was linked to 
autoimmunity in human patients.  (Dominguez-Villar and Hafler, 2018). Of special note for 
this thesis is atherosclerosis, which is a chronic inflammatory disease characterized by the 
formation of arterial plaques. A number of different immune cells infiltrate these plaques 
including macrophages, DCs and T cells. Over time the plaque hardens and narrows the 
arteries limiting the flow blood. Even worse, these plaques can rupture resulting in thrombus 
formation and vessel occlusion as seen in myocardial infarctions and stroke. CD4+ T cells 
promote plaque formation and decrease stability of atherosclerotic lesions, which 
consequently affects the clinical outcome of this disease. It is becoming increasingly clear that 
Treg cells inhibit plaque growth in murine models of atherosclerosis. Interestingly, an 
increasing amount of clinical studies do indeed suggest an association between higher 
numbers of Treg cells and a more favorable disease prognosis. Substantial efforts are 
currently being made to utilize Treg-based therapeutic approaches to cure inflammatory 
diseases including atherosclerosis (Ait-Oufella et al., 2006; Andersson et al., 2010). 
. 
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6 STUDY AIM 
The overall aim of this thesis is to gain a better understanding on how Treg cells suppress 
immune responses and how FOXP3 isoforms regulate immunity. 
In paper I we studied the role of Treg cell mediated suppression of dendritic cells and in 
particular the role of the inhibitory receptor CTLA-4. 
Paper II to IV focus on the function of FOXP3 isoforms. In paper II we studied the role of 
FOXP3fl and FOXP3D2 in atherosclerosis. Furthermore, in paper III and IV we studied the 
FOXP3Δ2 isoform in two related IPEX patients to get a better understanding how FOXP3Δ2 
acts in vivo. In paper III we studied the clinical manifestation and phenotype of Treg cells and 
in paper IV we focused on transcriptomic analysis of FOXPD2 expressing Treg cells.  
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7 MATERIAL AND METHODS 
The majority of the techniques used in this thesis are commonly used tools within the 
immunological and medical research fields. Unique methods include the generation of our 
Ctla4ex2fl/flFoxp3-Cre mouse strain, the in vitro DCs suppression assay in paper 1 and methods 
for FOXP3 isoform detection used throughout paper II – IV. For a more detailed description of 
these techniques see sections below.   
Table 2:  summarized the methods used per paper and for a more detailed description see 
corresponding papers.   
Table 2: Methods used in study 1 to 4. 
Methods 
Paper 
I II III IV 
Bone marrow chimeras x    
Chromatin immunoprecipitation  x   
Clinical patient data  x x  
Cytokine Bead array x    
Flow cytometry-based cell sorting x x  x 
Human specimens  x x x 
In vitro cell assays x x   
Lentiviral transduction  x   
Mouse models x    
Multi-color flow cytometry x x x x 
PCR x    
qPCR  x   
RNA sequencing x x  x 
Sanger sequencing   x  
SDS-PAGE and western blot  x   
X-inactivation methods   x  
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7.1 GENERATION OF CTLA4EX2FL/FLFOXP3-CRE MOUSE 
 
We generated conditional Ctla4ex2fl/flFoxp3-
Cre knockout mice by inserting LoxP sites on 
both sides of exon 2 of CTLA-4. In brief, a 
targeting construct was generated from a 
C57BL/6 bacterial artificial chromosome 
(BAC) (clone RP23:388N14). The construct 
had a long homology arm which extended 
6.01 kb 5ʹ to the single LoxP site and the short   
homology   arm extended   2.02 kb   3ʹ   to   the   
LoxP/ FRT-flanked neo cassette. The targeting 
construct was linearized using NotI prior to 
electroporation into C57BL/6 embryonic stem 
cells, the stem cells were then microinjected 
into blastocysts from BALB/c mice. To remove 
the Neo cassette, the chimera was crossed 
with C57BL/6 Flp mice. Ctla4ex2fl/fl mice were 
mated with Foxp3-Cre mice (C57BL6/J 
background) to generate Ctla4ex2fl/flFoxp3-Cre 
mice (Figure 7).  
 
7.2 IN VITRO DCS SUPPRESSION AND T CELL PROLIFERATION 
For CD4+CD25+ Treg cells a single cell suspension was prepared from peripheral LNs 
(superficial cervical, axillary, brachial and inguinal) as well as mesenteric LNs. Cells were 
enriched for CD25 using CD25-PE antibody and anti-PE MicroBeads (Miltenyi Biotec). For the 
enrichment step either manual selection columns or the AutoMACS positive selection 
program was used. CD25+ enriched cells were then labeled with CD4-APC antibody and 
CD4+CD25+ Treg cells were sorted using flow cytometric cell sorting. For Treg cell activation 
cells were pre-activated for 3 days. In brief, cells were cultured for 48h in the presence of 5 
µg/mL plate-bound anti-mouse CD3, 500 U/mL recombinant IL-2 and rested for 24h in 500 
U/mL recombinant IL-2. CD4+CD25- Effector T cells were isolated in a similar manner to Treg 
cells from single cell suspensions prepared from LNs. 
For CD11c+ DCs isolation a single cell suspension was prepared from spleens. T cells, B cells 
and NK cell were depleted by labeling cells with a cocktail antibody mix in combination with 
anti-biotin beads and using depletion columns (Miltenyi). The negative fraction was labeled 
with anti-CD11c+ micro beads (Miltenyi Biotec) and CD11c+ DCs were positively selected 
using a manual column (Miltenyi Biotec). 
Figure 7: The Ctla4ex2fl/flFoxp3-Cre mouse strain is 
homozygote for Cre. Breeding pairs Ctla4ex2fl/wtFoxp3-Cre to 
generate wild type litter mates and Ctla4ex2fl/flFoxp3-Cre 
animals.  
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Pre-activated Treg cells were co-cultured in a 1:1 ratio with CD11c+ DCs in the presence of 
100 ng/ml LPS. After 24 hours cells were either analyzed using flow cytometry or resorted for 
either T cell proliferation assay or RNAseq. For the T cell proliferation assay DC were co-
cultured with effector T cells in a 1:10 ratio (DC : Teff) in the presence of 0.25µg/ml soluble 
aCD3. After 72 h cell proliferation was measured by thymidine incorporation (Figure 8).  
 
7.3 FOXP3 ISOFORM DETECTION 
In this thesis, three methods were used to detect FOXP3 isoforms, namely qPCR, flow-cytometry and 
western blot. All three methods have technical limitations but combined give a reasonable 
quantification of isoform expression (Figure 9). 
 
A combination of different primer pairs (Table 3)  that bind to exon boundaries were used to 
calculate FOXP3 expression using qPCR. As primer pairs are not equally efficient in amplifying 
DNA we determined and corrected for the efficiency for the different pairs. The sum of 
FOXP3ex1-2 and FOXP3ex1-3 (FOXP3Δ2) was used to calculate total FOXP3 mRNA expression. 
Splice-variant ratio was calculated as followed: (FOXP3variant/FOXP3total)*100. 
Figure 9: Detection of FOXP3 isoforms using antibodies and PCR primer pairs. 
Figure 8: in vitro DCs suppression assay and T cell proliferation assay 
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Table 3: FOXP3 primers for exon boundary detection. 
Exon detection  Primer sequence 
exon 2+ forward 5’--- TTC ATG CAC CAG CTC TCA AC---3’ 
reverse 5’---GCC TTG AGG GAG AAG ACC---3’ 
exon 7- forward 5’---GAG CAG CAG GCA TCA TCC G---3’ 
reverse 5’---CTG GGA ATG TGC TGT TTC C---3’ 
exon 2- forward 5’--- GGA GGG CTG CAC CCA AAG ---3’ 
reverse 5’--- CCG TTG AGA GCT GCA GCT GC ---3’ 
 
On protein level we detected FOXP3 using the antibodies summarized in Table 4. For flow 
cytometry two antibody clones were used to either detect total FOXP3 expression using 
236A/E7 (FOXP3tot) or the presence of exon 2 using the 150D/E4 (FOXP3ex2) clone. The latter 
one was used to detect FOXP3fl. MFI values of both FOXP3tot FOXP3ex2 were first normalized 
to naïve T cells. FOXP3tot/FOXP3ex2 ratio was calculated using normalized MFI values. 
Alternative splicing of exon 7 can be best studied at transcriptomic level since no currently 
commercially available antibody exists that recognizes exon 7.   
Table 4: antibody clones for FOXP3 detection 
Clone Epitope side Application  Species 
150D/E4 exon 2 FACS 
Human  236A/E7 Region exon 3 - 6 FACS 
eBIO7979 Region exon 3 - 6 Western Plot 
FJK-16s exon 2 FACS mouse 
In western blot we used an antibody clone detecting all FOXP3 isoforms. FOXP3 isoforms were 
distinguished based on molecular weight with FOXP3fl having the biggest one (47 kDa). 
FOXP3D7 (44 kDa) and FOXP3D2 (43 kDa) are too close in their molecular weight to be 
properly distinguished. Both FOXP3D7 and FOXP3D2D7 (40 kDa) are both expressed at a too 
low level (based on data from qPCR) to be reliably quantified using this method.  
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8 RESULTS AND DISCUSSION 
8.1 PAPER I 
It is well established that Treg cells constitutively express the coinhibitory molecule CTLA-4, 
which is essential for Treg cells to function. However, it remains controversial as to how CTLA-
4 exerts its function. In this study we generated a conditional knockout mouse model to study 
the relative contribution of cell-intrinsic and cell-extrinsic actions mediated by CTLA-4 on Treg 
cells. These Ctla4ex2fl/flFoxp3-Cre mice express only the naturally occurring ligand 
independent isoform of CTLA-4 in Treg cells. This CTLA-4 isoform is unable to interact with 
CD80 and CD86 on antigen presenting cells. Importantly, the expression of CTLA-4 was not 
affected in other immune cells as seen by the normal CTLA-4 expression in effector T cells. As 
previously shown, CTLA-4 is an important marker for Treg function and mice lacking complete 
CTLA-4 expression either specifically in Treg or as germ line deficiency, die from 
lymphoproliferative disorders. One of the key findings in this study is that Ctla4ex2fl/flFoxp3-
Cre mice did not develop a lymphoproliferative phenotype. Instead, they appeared overall 
healthy at 6-10 weeks of age similar to their wild type litter mates. In contrast, mice 
completely devoid of CTLA-4 in Treg cells developed lymphoproliferative disease. The 
previous study by Wing et al. demonstrated that mice completely devoid of CTLA-4 in Treg 
cells die at 10 weeks of age due to lymphoproliferative disease. We believe the discrepancy 
seen between these studies is that our mice were on a C57BL/6 background whereas the 
previous study used a BALB/c background. When we extended our study, we saw that older 
Ctla4ex2fl/flFoxp3-Cre mice (6 months) developed an inflammatory phenotype in the lung. It is 
tempting to speculate that this is due to a different functional phenotype of peripherally 
induced Treg cells as they are believed to play a role in maintaining tolerance at 
environmental exposed surfaces including the lung. To answer this question, we could 
transfer CD45.2+CD4+GFP- cells from a Ctla4ex2fl/flFoxp3-CreFoxp3-GFP reporter mouse to a 
CD45.1+ host and study function. Furthermore, we saw an increased thymic output of Treg 
cells. This is in contradiction to studies done in mice having LoxP3 sites around exon 2 and 3 
of CTLA-4 (Wing et al., 2008). This may be due to differential efficiency of the Cre-mediated 
recombination between the different studies, but it remains unknown why that would be the 
case. Furthermore, it was also shown that when CTLA-4 deletion is introduced during 
adulthood, mice do not develop a lethal phenotype (Klocke et al., 2016; Paterson et al., 2015)  
We did not see an increase in Teff cell numbers nor any change in the expression of co-
stimulatory molecules on DCs. However, Ctla4ex2fl/flFoxp3-Cre mice had an increased number 
of Treg cells, in particular with Treg cells lacking CD25 expression. The dramatic increase of 
Treg cells could potentially compensate for any functional impairment due to altered CTLA-4 
expression. Thus, we isolated Treg cells for in vitro assays to further investigate Treg cell 
function and using an DC suppression assay that we established. We found that Treg cells 
isolated from Ctla4ex2fl/flFoxp3-Cre were able to control CD80 and CD86 expression. When it 
comes to CTLA-4 mediated suppression, transendocytosis has suggested to be an important 
functional mechanism. Our data does not contradict that transendocytosis can happen but it 
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supports the idea that it is not an essential pathway for Treg cell mediated suppression. Here 
it is important to note that most of the studies concerning transendocytosis have not used 
Treg cells but rather Teff cells or transduced cell lines. Also, we have been unable to replicate 
some of these findings. I strongly believe that these experiments should be repeated in a 
context with actual Treg cells before we speculate that transendocytosis contributes to the 
suppressive ability of Treg cells. Interestingly, Treg cells isolated from Ctla4ex2fl/flFoxp3-Cre 
failed to support upregulation of PD-L2 on suppressed DCs. We speculate that this is due to 
the interaction of CTLA-4 with CD80 and/or CD86. A potential next set of experiments would 
be to address this question by isolating DCs from CD80/CD86 knock out mice and use them in 
our in vitro suppression assay. 
When we looked at Treg cell mediated suppression of DCs to determine whether Treg cells 
either suppress the maturation of DCs or DCs function we found that Treg cells do not inhibit 
the maturation process but rather induce an anti-inflammatory program in these cells. For 
this part of the study we used RNAseq data from DC suppressed by wild type Treg cells. We 
originally were planning to include DCs suppressed by Treg cell isolated from Ctla4ex2fl/flFoxp3-
Cre mice, however the RNA-sequencing from this group unfortunately failed. Changes in RNA 
transcription does not automatically indicate corresponding protein levels will be altered 
(Vogel et al., 2010). Therefore, it would be interesting to see how Treg cells might affect the 
induction of an anti-inflammatory phenotype on additional levels of the gene expression 
pathway, for example by regulation of mRNA translation. Furthermore, it was shown that LPS 
exposure in DCs results in epigenetic changes (Saeed et al., 2014). Ideally it would be 
interesting to also focus on epigenetic changes.   
Since Treg cell sorting for functional assays rely on extracellular markers we were not able to 
include FOXP3+CD25- cells to assess their function.  It would be possible to backcross our mice 
strain to mice expression GFP under the FOXP3 promoter (Fontenot et al., 2005b). This would 
give us the possibility to use GFP in combination with CD25 to isolate both FOXP3+CD25+ and 
FOXP3+CD25- cell populations. However, due to limitation in both time and recourses we did 
not pursue this line of experiments. In this regard it would be of general interest to establish 
the transcriptional profile of these Ctla4ex2fl/flFoxp3-Cre Treg cells to answer the question how 
they differ in respect to wild type cells.  
When it comes to CTLA-4 research, most studies do not account for the presence of isoforms. 
This can be partly due to the limitation in methods. Antibodies available for flow-cytometry 
detect epitope in the ligand binding domain only, whereas there are antibodies clones 
described for western blot that bind to the cytoplasmic tail. However, when we attempted to 
use these antibodies to study any potential signaling of liCTLA-4 we were unable to get them 
to work. An alternative strategy to study CTLA-4 signaling would be to introduce a biochemical 
tag such as a FLAG tag. We know the consequences of failed CTLA-4 signaling but it is still not 
fully understood how CTLA-4 signals. 
In summary, we do not rule out that transendocytosis may occur, but it remains to be seen 
whether it contributes to the suppressive ability of Treg cells. In fact, our data suggests that 
this may not be the case. One major part that is lacking in respect to CTLA-4 is a better 
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understanding of its signaling, especially in the context of liCTLA-4. Moreover, little is known 
about the functional role of both liCTLA-4 and 1/4CTLA-4. In contrast it was shown that sCTLA-
4 seems to be more prevalent in naïve T cells and that flCTLA-4 is upregulated during T cell 
activation. It would have been interesting to see if cell activation alters the ratio between 
expressed CTLA-4 isoforms.  
 
8.2 PAPER II 
When it comes to studying FOXP3 isoform we face several limitations with regards to available 
reagents. Techniques to detect FOXP3 mRNA species include qPCR, mRNA sequencing (both 
single cell and bulk) and Northern blot. On protein level methods like flow cytometry and 
western blot rely on antibody binding and are widely used. Commercially available clones only 
bind either exon 2 expressing isoforms or all four isoforms simultaneously. So far, our efforts 
to produce an antibody binding in the exon 7 region has not been successful. I believe that 
one of the most important advances in studying FOXP3 isoforms would be to generate 
monoclonal antibodies towards the exon/exon junctions in the various FOXP3 isoforms.  Such 
antibodies could potentially be used for both western blot and flow cytometry and would 
greatly facilitate studies on expression of FOXP3 isoforms. 
One of the key findings in this study is that during Treg cell activation the overall upregulation 
of FOXP3 expression is mainly due to an increased expression of the isoforms FOXP3D2. 
These findings were confirmed using qPCR and on protein level using Flow cytometry and 
Western blot. However, this contradicts the findings in the recently published study by 
Lundberg at al. (2017) where they showed that increased FOXP3 expression after TCR 
stimulation was mainly due to an increase in exon 2 expression (Lundberg et al., 2017). It is 
noteworthy that the latter study did not study FOXP3 expression in Treg cells, but rather Teff 
cells, nor did they confirm their results by either western blot or PCR. It is also unclear how 
the quantification of FOXP3 isoforms is performed as the reference lines displayed are clearly 
off the population centers in the FACS density plots.  
It is difficult to assess the role of FOXP3 isoforms in an in vivo situation since mice do not 
express similar isoforms. However, in a study published in 2015 a mouse model with a knock-
in construct replacing FOXP3fl with a version lacking exon 2 and 7, FOXP3d2d7. These mice 
developed a phenotype similar to scrufy mice and this finding supports in vivo data from 
human Treg cells that showed that the lack of exon 7 results in the loss of FOXP3 suppressive 
function (Joly et al., 2015). A similar approach could be used to study FOXP3D2. Such a mouse 
model would not only give us tools for in vivo experiments but also answer the question of 
whether the observed phenotype of mice is due to the forced expression of an isoform that 
does not exists naturally in mice or it is a result of functional differences between FOXP3 
isoforms.  
Another key finding in this study is that increased FOXP3D2 expression correlates with better 
plaque stability indicating that aTreg cells might limit disease progression. This demonstrates 
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the importance to not only use total FOXP3 expression as marker for Treg function and that 
Treg cell number alone does not necessary correlate to the suppressive activity. Interestingly, 
we did not find this correlation when looking at peripheral blood Treg cells and plaque 
stability. This illustrates the limitation of studying peripheral blood and the need to include 
additional specimens when possible. 
One limitation of this study is we study gene expression of bulk cells. This created challenges 
to correlate the expression of molecules induced by FOXP3D2, such as GARP, with disease 
progression as they can be expressed by non-Treg cells. One way to address the question 
regarding heterogeneity of gene expression in plaque cells would be to run single cell RNA-
seq of either all cells, T cells or Treg cells. Bulk sequencing of sorted T cells or Treg cells would 
also be helpful. As we are working with large patient cohorts this is currently cost-prohibitive. 
It may also be possible to estimate the Treg contribution to total gene expression by 
computational methods such as of complete deconvolution CDSeq (Monaco et al., 2019). All 
these strategies would allow us to specifically correlate gene expression in Treg cells with 
vascular symptoms. 
In summary, we found that FOXP3D2 expression correlates with better atherosclerotic plaque 
stability and as expected FOXP3D2 controls a subset of genes partially different from FOXP3fl. 
A natural next step is to address the function of FOXP3D2 regulated genes in either animal 
models for atherosclerosis or clinical samples. I favor the latter strategy as the mice do not 
express Foxp3 isoforms and animal models for atherosclerosis do not exhibit unstable 
plaques. 
 
8.3 PAPER III & IV 
Studying human diseases give is us the option to get a better understanding of biological 
possesses in vivo. FOXP3 isoform research in human is mainly conducted using healthy 
controls that express both isoforms. Hence, studying single isoforms is either restricted to in 
vitro experiments or artificial models using mice. IPEX by itself is a rare disease and in study 3 
and 4 we had the unique opportunity to study the effect of a novel mutation 
(NM_014009.3:c.305delT) in exon 2 that results in a frameshift and the loss of FOXP3fl and 
any isoform expressing exon 2.  As a consequence, Treg cells in this patient express only one 
functional suppressive isoform, namely FOXPD2 (and undetectable levels of FOXP3D7). One 
of the most striking findings is that both patients have a relative mild phenotype in respect 
to their IPEX diagnosis. In particular the older male did not show any IPEX related symptoms 
until his 40ies. Both patients carry the same mutation in FOXP3 but we cannot rule out that 
additional mutations, that we did not check for, contribute to the more severe phenotype in 
the younger male. Furthermore, environmental factor most likely contributed to the 
difference in clinical manifestation. 
These patients show that FOXP3D2 by itself is capable to induce and maintain Treg cell 
differentiation. Based on the milder phenotype we at least know that these Treg cells have 
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an impaired function but are functional enough to prevent systemic fatal break of immune 
tolerance. However, looking at the female carrier we saw that only around 20% of Treg pool 
where c.305delT Treg cells a ratio that cannot be explained by random X-chromosome 
inactivation. We speculated that that either during Treg cell differentiation wild type Treg cells 
are favored or that c.305delT Treg cells do not survive in the periphery. One way to answer 
the question is to look at pTreg cell and tTreg cell development in both the patient and the 
female carrier. So far, the only partly repayable method to distinguish pTreg and tTreg cells is 
to look at epigenetic factors regulating the Foxp3 gene. It would be interesting to see in the 
mother how wild type Treg cell differ in this respect to c.305delT Treg cells. Furthermore, a 
study the kinetics of FOXP3 expression in vitro by induction of FOXP3 in the presence of TGF-
b and IL-2 could give us an indication if c.305delT Treg cells have impaired stability.  
We looked at the transcriptional profile of rTreg cells and aTreg cells of both male patients 
and found indications that c.305delT Treg cells display reduced lineage stability. We found 
significant changes in genes (ID3, Bcl6, eIF4E and MAP4K8) associated with lineage plasticity 
when comparing with healthy controls. Furthermore, using gene set enrichment analysis, we 
found indications that c.305delT Treg cells might have an impaired function in respect to 
mRNA processing.   Importantly, we had only two biological replicates from the IPEX group 
we and therefore used technical replicates for RNA-seq. This is not optimal but not 
unexpected as IPEX is such a rare disease and that results from multiple mutations. As the 
phenotype is mild it is unlikely that similar patients even will receive an IPEX diagnosis as 
exemplified by the advanced age at which our patients were diagnosed. The findings from 
these patients at least gives us an indication how FOXPD2 works in a human in vivo setting. In 
case we would get more blood samples we potentially could look at FOXP3D2 binding 
partners and targets by e.g. ChipSeq. Furthermore, we could design an in vitro setting similar 
as descried in paper 2 and compare findings from transduced cells with patient data.  
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9 CONCLUDING REMARKS 
With an increased understanding of Treg cell biology we now know that Treg cells comprise a 
heterogenous population of cells. How Treg cells are defined in humans have evolved since 
they were rediscovered in the mid 1990s. From being known as CD4+CD25+ T cells to being 
defined CD4+CD25highCD127low with FOXP3 as a key regulator. This has further evolved with 
the discovery that Teff cells transiently express FOXP3 and that rather the de-methylated 
status of the FOXP3 locus determines stable FOXP3 expression in Treg cells. Furthermore, 
FOXP3 isoform expression introduces another level of complexity into Treg cell 
characterization. In this thesis we showed the functional differences between the FOXP3 
isoforms FOXP3fl and FOXPD2 in respect to Treg cells activation and lineage stability. 
Furthermore, we demonstrated that Treg cells are capable to maintain immune homeostasis 
independent of CTLA-4 ligand binding and that CTLA-4 mediated cell intrinsic signaling is 
capable to induce an anti-inflammatory phenotype on DCs. Our findings challenge idea of the 
central role of the CTLA-4 binding domain in CTLA-4 mediated suppression.  
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